Carbohydrate Antigen 125-guided Therapy in Heart Failure

Inclusion Criteria: * Age 18 years or older. * At least 1 admission for AHF, in the last 180 days. * Demonstrates functional New York Heart Association status of Class ≥II at the moment of enrollment. * Objective evidence, either during the index admission or at least 180 days before enrollment, of a structural or functional abnormality of the heart at rest, and defined as: N terminal-pro-brain natriuretic peptide \>1000 pg/ml or brain natriuretic peptide \>100 pg/ml or echocardiographic abnormalities congruent with HF diagnosis such as: systolic left ventricular dysfunction (LVEF \<50%); left ventricular hypertrophy (defined as left ventricular septum or left ventricular posterior wall thickness ≥12 millimeters or left ventricular mass index \>104 g/m2 in women or 116 g/m2 in men); Ee'\>15 or significant valvular heart disease (moderate-severe). * A plasma CA125 value \>35 U/ml in a recent test evaluation (at least 30 days before enrollment, and preferably assessed before hospital discharge). * Patient must be capable of understanding and signing an informed consent form. Exclusion Criteria: * Life expectancy \<12 months due to other diseases different from HF. * Having undergone a cardiac transplantation, coronary revascularization procedure (percutaneous coronary intervention and/or coronary artery bypass grafting) or cardiac valve replacement in the past 3 months. * Angina pectoris higher than class II (Canadian Cardiovascular Society Classification). * Pregnancy at the moment of enrollment. * Valvular heart disease already scheduled for surgical intervention. * Severe chronic obstructive and/or restrictive pulmonary disease, requiring continuous oxygen administration. * Serum creatinine level \> 3 mg/dl or chronic renal insufficiency on dialysis treatment. * Patients receiving resynchronization therapy during the index admission. * Significant concurrent medical diseases including cancer or a history of cancer within 5 years of entering the screening period, endometriosis, cirrhosis, acute coronary syndrome within 6 months, uncontrolled hypertension, history of human immunodeficiency virus (HIV) infection, or a significant active infection. * Participating in another randomized study.